Application of multiple criteria decision analysis (MCDA) for the selection of pharmacological treatments / Aplicação da análise de decisão baseada em múltiplos critérios para seleção de tratamentos farmacológicos

Juliana Pereira de Castro, Gabriela Bittencourt Gonzalez Mosegui, Talita Martins Alves da Costa

Abstract


Introduction: Health Technology Assessment (HTA) is a tool that assists in the management of health systems, in which economic assessments are frequently applied. It is possible that the use of multicriteria analysis (MCDA) increases the quality of decisions. Objective: Identify the potentialities of the application of Multiple Criteria Decision Analysis (MCDA) in studies that used this type of method for the selection of treatments. Methods: An integrative review was executed based on articles where MCDA methods had been applied for the selection of treatments between February and April 2017 in the following databases: Pubmed (MEDLINE), Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), Embase, Science Direct, Scopus, Web of Science and Wiley Online Library. Results: Eighteen studies published between 1998 and 2017 in which different MCDA techniques were applied were selected. Growth in the number of published studies was observed, showing increasing interest in the use of this type of method in health decision making. Conclusion: MCDA may guide more adequate decisions compared to the traditional Health Technology Assessment (HTA) methods and has the potential to help in the selection of treatments and the construction of medicines’ lists.


Keywords


Biomedical technology, Technology assessment, biomedical, Therapeutics, Review.

Full Text:

PDF

References


Al-Bradriyeh D, Allabadi I, Fahey M, Al-Khal A, Zaidan M. Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. Clin Ther. 2016 Mai, 38(5):1158-73. Available in: .

Araujo DV, Souza CPR, Bahia LR, Rey HCV, Santos Junior B, Tura BR, et al. Análise de Custo-Efetividade da Sinvastatina versus Atorvastatina na Prevenção Secundária de Eventos Cardiovasculares no Sistema Único de Saúde Brasileiro. Value Health. 2011 Jul-Ago, 14(5):S29-S32. Available in: .

Brasil. Ministério da Saúde. Diretrizes Metodológicas: elaboração de uma revisão sistemática e metanálise de ensaios clínicos randomizados. Brasília: MS, 2012. Available in: .

Broekhuizen H, Groothuis-Oudshoorn CGM, Hauber AB, Jansen JP, Ijzerman MJ. Estimating the value of medical treatments to patients using probabilistic multi-criteria decision analysis. BMC Med Inform Decis Mak. 2015 Dez, 15(102):1-10. Available in: .

Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013 Nov, 6(6):724-31. Available in: .

Chen, R.; Chiu, J.; Bau, C. The recommendation of medicines based on multiple criteria decision making and domain ontology: an example of anti-diabetic medicines. In: International Conference on Machine Learning and Cybernetics, 2011. Available in: .

Chong PH, Seeger JD, Franklin C. Clinically Relevant Differences between the Statins: Implications for Therapeutic Selection. Am J Med. 2001 Out, 111(5):390-400. Available in: .

Devlin NJ, Sussex J. Office of Health Economics – OHE. Incorporating multiple criteria in HTA – Methods and Processes. Londres. 2011 Mar. Available in: .

Erjaee A, Bagherpour M, Razeghi S, Dehghani SM, Imanieh MH, Haghighat M. A multi-criteria decision making model for treatment of Helicobacter pylori infection in children. HK J Paediatr. 2012 Dez, 17:237-42. Available in: .

Fang N, Yao M, Tseng T. On evaluating the efficiency of similar therapeutic-effect drugs using multi-criteria decision-making approaches selection result. In: International Conference on Computers and Industrial Engineering (CIE).2010 (40). Available in: .

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the EVIDEM Framework to Medicines Appraisal. Med Decis Making. 2012 Mar-Apr, 32(2):376-88. Available in: .

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence, and value: impact on decision making – the EVIDEM framework and potential applications. BMC Health Serv Res. 2008 Dez, 8(270):1-16. Available in: .

Goetghebeur MM, Wagner M, Nikodem M, Zyla A, Micaleff A, Amzal B. Pragmatic multicriteria decision analysis (MCDA) combined with advanced pharmacoepidemiology for benefit-risk assessments of medicines adapted to the real-life constraints of regulators: development and case study. Ther Innov Regul Sci. 2016 Abr, 50(5):620-31. Available in: .

Greef-van der Sandt I, Newgreen D, Schaddelee M, Dorrepaal C, Martina R, Ridder A, et al. A quantitative benefit-risk assessment approach to improve decision making in drug development: application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder. Clin Pharmacol Ther. 2016 Abr, 99(4):442-51. Available in: .

Hoshikawa K, Ono S. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting. J Clin Pharm Ther. 2017 Fev, 42(1):80-6. Available in: .

Hsu JC, Hsieh C, Yang YK, Lu CY. Net clinical benefit of anticoagulants: a multiple criteria decision analysis. PLOS One. 2015b Abr, 10(4):1-15. Available in: .

Hsu JC, Tang DH, Lu CY. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis. Int J Clin Pract. 2015a Abr, 69(4):436-43. Available in: .

Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012, 7(74):1-8. Available in: .

Kolasa K, Zwolinski KM, Kalo Z, Hermanowski T. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet J Rare Dis. 2016 Mar, 11(23):1-12. Available in: .

Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics. 2014 Abr, 32(4):345-65. Available in: .

Marsh K, Zaiser E, Orfanos P, Salverda S, Wilcox T, Sun S, et al. Evaluation of COPD treatments: a multicriteria decision analysis of aclidinium and tiotropium in the United States. Value Health. 2017 Jan, 20(1):132-40. Available in: .

Mendeley. Mendeley Reference Manager Ltd, 2018. Available in: .

Nita ME, Secoli SR, Nobre M, Ono-Nita SK. Métodos de pesquisa em avaliação de tecnologia em saúde. Arq Gastroenterol. 2009 Out-Dez, 46(4):252-5. Available in: .

Nwokoro E, Leach R, Ardal C, Baraldi E, Ryan K, Plahte J. An assessment of the future impact of alternative technologies on antibiotics markets. J Pharm Policy Pract. 2016 Out, 9(34):1-12. Available in: .

Perez Encinas M, Fernandez MA, Martin ML, Calvo MV, Gomez-Alonso A, Dominguez-Gil A, et al. Multicriteria Decision Analysis for Determining Drug Therapy for Intermittent Claudication. Meth Find Exp Clin Pharmacol. 1998 Jun, 20(5):425-31. Available in: .

Pinto DM, Mandil A. Claudicação intermitente: do tratamento clínico ao intervencionista. Rev Bras Cardiol Invas. 2005, 13(4):261-9. Available in: .

Ramli A, Aljunid SM, Sulong S, Yusof FAM. National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool. Ther Clin Risk Manag.. 2013 Dez, 9:491-504. Available in: .

Saaty TL. How to make a decision: the analytic hierarchic process. Euro J Oper Res. 1990 Set, 48(1):9-26. Available in: < https://www.sciencedirect.com/science/article/abs/pii/037722179090057I>.

Schey C, Krabbe PFM, Postma MJ, Connoly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis. 2017 Jan, 12(10):1-9. Available in: .

Souza, M. T.; Silva, M. D.; Carvalho, R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo). 2010 Jan-Mar, 8(1):102-6. Available in: .

Tervonen T, Valkenhoef G, Buskens E, Hillege HL, Postmus D. A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis. Statist Med. 2011 Jan, 30(12):1419-28. Available in: .

Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016 Jan, 19:1-13. Available in: .

Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012 Out, 15:1172-81. Available in: .

Vanni T, Stein AT, Souza KM, Freitas MG, Patterson I, Assis EC, et al. Inteligência avaliativa em rede: construindo consenso em Avaliação de Tecnologias em Saúde. Rev Eletron de Comum Inf Inov Saúde. 2015 Out-Dez, 9(4):1-10. Available in: .

Vidal AT, Santos VCC, Passos JEF, Petramale CA. Priorização de protocolos clínicos para atenção integral às pessoas com doenças raras: análise de decisão multicritério. Revista Eletrônica Gestão e Saúde.2015 Out, 6(supl. 4):3094-110. Available in: < http://periodicos.unb.br/index.php/rgs/article/view/22101/15797 >.

Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005 Dez, 52(5):546-53. Available in: .




DOI: https://doi.org/10.34119/bjhrv3n5-146

Refbacks

  • There are currently no refbacks.